Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Servidei, Serenella
STRIDE, NCT04535609 / 2020-002855-40: An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients	Completed	2	213	Europe, Canada, US, RoW	Mavodelpar, REN001, Placebo	Reneo Pharma Ltd	Primary Mitochondrial Myopathy	09/23	10/23
PMD-OPTION, NCT05972954 / 2022-003307-16: OMT-28 in Patients With Primary Mitochondrial Disease (PMD)	Active, not recruiting	2	32	Europe	OMT-28	Omeicos Therapeutics GmbH, OMEICOS Therapeutics GmbH	Primary Mitochondrial Disease	03/25	06/25